A Phase 3, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib Versus Ibrutinib as 1L+ Therapy in Participants with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011)